In a post hoc analysis, LDL concentrations of less than 55 mg/dL at 1, 2 and 3 years were observed in 42%, 45%, and 42%, respectively, of patients in the combination therapy group and 25%, 29% and 25%, respectively, of patients in the high-intensity statin monotherapy group, for absolute differences of 17.5 percentage points at 1 year (95% CI, 14.3-20.7), 14.9 percentage points at 2 years (95% CI, 11.7-18.2) and 14.8 percentage points at 3 years (95% CI, 11.2-18.3).
LDL concentrations of less than 70 mg/dL at 1, 2 and 3 years were observed in 73%, 75%, and 72%, respectively, of patients in the combination therapy group, and in 55%, 60% and 58%, respectively, of patients in the high-intensity statin monotherapy group (absolute differences = 17.5 percentage points at 1 year 14.9 percentage points at 2 years 14.8 percentage points at 3 years P for all =. The primary endpoint occurred in 9.1% of participants in the combination therapy group and 9.9% in the high-intensity statin monotherapy group, for an absolute difference of –0.78 percentage points (90% CI, –2.39 to 0.83). The primary endpoint was the 3-year composite of CV death, major CV events or nonfatal stroke. Researchers randomly assigned participants to moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 10 mg with ezetimibe 10 mg) or high-intensity statin monotherapy (rosuvastatin 20 mg). In the RACING study, Jang and colleagues analyzed data from 3,780 adults with ASCVD from 26 clinical centers in South Korea, enrolled between February 2017 and December 2018 (mean age, 64 years 75% men 40% with previous MI 37% with diabetes). “This would contribute to a reduction in the adverse effects or potential intolerances related to high-intensity statin therapy.” “Compared with high-intensity statin alone, the addition of ezetimibe to lower-intensity statin could provide an alternative strategy to not only achieve adequate LDL cholesterol concentrations but also reduce the required dose of statins,” Yangsoo Jang, MD, PhD, of CHA Bundang Medical Center and CHA University College of Medicine in Seongnam, South Korea, and colleagues wrote in The Lancet. The findings suggest that ezetimibe combination therapy might be considered earlier in the use of moderate-intensity statin therapy, rather than doubling the statin dose for patients at high risk for adverse effects or statin intolerance with high-intensity statin therapy.ĭata were derived from Kim BK, et al.
Moderate intensity statin plus#
If you continue to have this issue please contact to HealioĪmong adults with atherosclerotic CVD at very high risk, moderate-intensity statin plus ezetimibe combination therapy was noninferior to high-intensity statin monotherapy for major CV outcomes at 3 years, including CV death, data show.